

A Family of Products for Flexibility in iNO Dosing



LungFit® PH



LungFit® PRO



LungFit® GO

Use location	Hospital NICU setting	Hospital setting	At-home treatment
For treatment of	Term and near-term neonates with hypoxic respiratory failure, commonly referred to as persistent pulmonary hypertension of the newborn (PPHN)	Community-acquired viral pneumonia (including COVID-19) and bronchiolitis	Nontuberculous mycobacteria (NTM) lung infection and in patients with underlying chronic obstructive pulmonary disease (COPD), suffering from persistent lung infections
iNO concentration	Low-concentration iNO: ≤80 ppm	High-concentration iNO: 80 to 400 ppm	High-concentration iNO: 80 to 400 ppm
Supplemental oxygen can be utilized through the system	✓	✓	—
Alarms to monitor performance	✓	✓	✓
Disposable NO ₂ Smart Filters	✓	✓	✓
System weight	~44 lb	~20 lb	~18 lb
Usable with standard 110V or 220V electric outlets	✓	✓	✓

For more information about the LungFit PH System, visit LungFitPH.com. Or, for more information about the LungFit family pipeline, visit BeyondAir.net/pipeline

The Benefits Of The First-In-Class Lungfit Technology

- Transforms iNO treatment** with simplicity and certainty to provide effective and efficient patient care
- Improves operating economics** for the hospital by avoiding cost and logistics associated with 45-lb high-pressure cylinder iNO treatment
- Reduces burdensome training, inventory, and storage requirements** by eliminating the need for iNO cylinders

- Convenient storage of small NO₂ Smart Filters and disposable accessories** at the point of care
- Enables integration of iNO management into hospital point-of-use solutions** for streamlined logistics
- Reduces risk of NO₂ exposure to patient and clinician** with NO₂ Smart Filter and integrated autopurging¹

Reference: 1. Rimkus M, Montgomery F, Bathe D. On-demand nitric oxide for ventilator-based nitric oxide inhalation: a risk-reduction perspective. Abstract presented at: 22nd Congress of the International Society for Aerosols in Medicine (ISAM); May 24, 2019; Montreux, Switzerland. Accessed May 13, 2022.

Caution: LungFit® PRO and LungFit® GO are investigational devices, limited by federal (or United States) law to investigational use.